The dual role of empagliflozin: Cardio renal protection in T2DM patients

被引：3
|
作者：
Shafiq, Aimen [1 ]
Mahboob, Eman [1 ]
Samad, Muhammad Ammar [1 ]
Rehman, Mohammad Hassam Ur [1 ]
Tharwani, Zoaib Habib [1 ]
机构：
[1] Dow Univ Hlth Sci, Dow Med Coll, Fac Med, Karachi, Pakistan
来源：
ANNALS OF MEDICINE AND SURGERY | 2022年 / 81卷
关键词：
Empagliflozin; Type 2 diabetes mellitus; Cardio protective; Reno protective; Side effects; COTRANSPORTER; 2; INHIBITOR; TYPE-2; DIABETES-MELLITUS; ESTABLISHED CARDIOVASCULAR-DISEASE; BETA-CELL DYSFUNCTION; DOUBLE-BLIND; SGLT2; INHIBITORS; ADD-ON; KIDNEY-DISEASE; OUTCOMES; RISK;
D O I：
10.1016/j.amsu.2022.104555
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Empagliflozin (Jardiance (R)) is an insulin independent antihyperglycemic agent used in treatment of T2D.The drug is a sodium glucose cotransporter-2 (SGLT2) inhibitor approved in USA and Europe and other countries of the world. As empagliflozin demonstrates cardioprotective and Reno protective properties its prime target are patients having CVD and CKD complicated by T2D. This review sheds light on mechanism of action of the drug and with the help of clinical outcomes establishes the use of empagliflozin in T2D patients.Although empagliflozin is a well-tolerated and easy to administer drug, it has some side effects and contraindications which are discussed in the article to help the reader weigh its beneficial effects against its adverse effect and understand its use in clinical medicine.
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Correlation of renal function indicators and vascular damage in T2DM patients with normal renal function
    Zhang, Yue-Yang
    Gui, Jing
    Chen, Bing-Xue
    Wan, Qin
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [32] Empagliflozin as Add-On to Metformin for 24 Weeks Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
    Haering, Hans-Ulrich
    Merker, Ludwig
    Seewaldt-Becker, Elke
    Weimer, Marc
    Meinicke, Thomas
    Broedl, Uli C.
    Woerle, Hans J.
    DIABETES, 2013, 62 : A282 - A282
  • [33] Lack of Interaction Between the Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin and Hydrochlorothiazide or Torasemide in Patients With T2DM
    Giessmann, Thomas
    Heise, Tim
    Macha, Sreeraj
    Mattheus, Michaela
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2012, 61 : A614 - A615
  • [34] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Pioglitazone with or without Metformin in Patients with Type 2 Diabetes (T2DM)
    Kovacs, Christopher Simon
    Seshiah, Veeraswamy
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans-Juergen
    Broedl, Uli C.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [35] Empagliflozin as Add-On to Pioglitazone With or Without Metformin Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
    Kovacs, Christopher
    Seshiah, Veeraswamy
    Swallow, Ros
    Jones, Russell
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2013, 62 : A291 - A291
  • [36] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Pioglitazone With or Without Metformin in Patients with Type 2 Diabetes (T2DM)
    Kovacs, Christopher S.
    Seshiah, Veeraswamy
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A273 - A273
  • [37] Empagliflozin Improves Beta-Cell Function Measured with the Hyperglycemic Clamp in T2DM
    Al Jobori, Hussein
    Daniele, Giuseppe
    Martinez, Robert
    Abdul-Ghani, Muhammad
    Adams, John
    Triplitt, Curtis
    Cersosimo, Eugenio
    Defronzo, Ralph A.
    DIABETES, 2016, 65 : A286 - A286
  • [38] Risk of cardiovascular disease in patients with T2DM
    Nature Reviews Endocrinology, 2013, 9 (6) : 316 - 316
  • [39] Distinct Mechanisms Are Responsible for the Increase in Endogenous Glucose Production and Ketone Formation following Empagliflozin in T2DM Patients
    Abdelgani, Siham
    Adams, John M., III
    Daniele, Giuseppe
    Almulla, Fahd
    Defronzo, Ralph A.
    Abdul-Ghani, Muhammad
    Abu-Farha, Mohamed
    Del Prato, Stefano
    DIABETES, 2022, 71
  • [40] NAFLD prevalence in older patients with T2DM
    Kotsiliti, Eleni
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2023, 20 (02) : 65 - 65
12345